Orthocell’s "Cell Factory" Validated For Bone Regeneration
• Cell factory-derived bioactive molecules from bone may enhance regeneration of slow healing bone defects common in chronic osteomyelitis
• These results were presented at the world leading Bone and Joint Infection Society (EBJIS) in collaboration with Institutes in, Sweden, Australia, Denmark, India and UK
•The study further validated the potential for a cost effective regenerative solution for chronic bone infection, combining Orthocell’s pipeline product with an antibiotic containing bone substitute.
Perth, Australia; 15 September 2015: Regenerative medicine company Orthocell Limited is pleased to announce the presentation of its successful ‘cell factory’ data at the European Bone and Joint Infection Society in Estoril Portugal September 2015. The data was generated as a result successful collaboration with institutes in Sweden, Australia Denmark, India and UK.
The study further supports Orthocell’sinnovative intellectual property around the generation of ‘tissue specific’ growth factors for the regeneration of cartilage and bone and follows on from the Cell Factory work for the cartilage injuries that was announced by Orthocell in May 2015.
This recent study has supported the role of growth factors and extracellular matrix proteins which were derived by the researchers from bone cells cultivated in a cell factory, to be combined with scaffolds, to regenerate serious bone defects.
“Unhealed fractures, particularly those involving infections is one of the most difficult orthopaedic conditions to treat and this work holds great promise for an effective solution” said Orthocell CEO Paul Anderson. “This has the potential to be a clinically effective and cost effective approach for the regeneration of chronic bone defects,” he said.
This has been a successful international collaboration for Orthocell with the Department of Orthopaedics, Clinical Sciences, Lund University, Sweden, The Centre for Orthopaedic Research, University of Western Australia, Australia, The Department of Orthopaedic Surgery, Rigshospitalet Copenhagen Denmark, The Department of Biological Sciences and Bioengineering, The Department of Biological Sciences and Bioengineering Indian Institute of Technology, Kanpur, India and Nuffield Orthopaedic Centre, Oxford University Hospitals United Kingdom.
This further showcases Orthocell’s exciting pipeline opportunities which are strongly complimentary to our current regenerative medicine approaches.
Help employers find you! Check out all the jobs and post your resume.
• These results were presented at the world leading Bone and Joint Infection Society (EBJIS) in collaboration with Institutes in, Sweden, Australia, Denmark, India and UK
•The study further validated the potential for a cost effective regenerative solution for chronic bone infection, combining Orthocell’s pipeline product with an antibiotic containing bone substitute.
Perth, Australia; 15 September 2015: Regenerative medicine company Orthocell Limited is pleased to announce the presentation of its successful ‘cell factory’ data at the European Bone and Joint Infection Society in Estoril Portugal September 2015. The data was generated as a result successful collaboration with institutes in Sweden, Australia Denmark, India and UK.
The study further supports Orthocell’sinnovative intellectual property around the generation of ‘tissue specific’ growth factors for the regeneration of cartilage and bone and follows on from the Cell Factory work for the cartilage injuries that was announced by Orthocell in May 2015.
This recent study has supported the role of growth factors and extracellular matrix proteins which were derived by the researchers from bone cells cultivated in a cell factory, to be combined with scaffolds, to regenerate serious bone defects.
“Unhealed fractures, particularly those involving infections is one of the most difficult orthopaedic conditions to treat and this work holds great promise for an effective solution” said Orthocell CEO Paul Anderson. “This has the potential to be a clinically effective and cost effective approach for the regeneration of chronic bone defects,” he said.
This has been a successful international collaboration for Orthocell with the Department of Orthopaedics, Clinical Sciences, Lund University, Sweden, The Centre for Orthopaedic Research, University of Western Australia, Australia, The Department of Orthopaedic Surgery, Rigshospitalet Copenhagen Denmark, The Department of Biological Sciences and Bioengineering, The Department of Biological Sciences and Bioengineering Indian Institute of Technology, Kanpur, India and Nuffield Orthopaedic Centre, Oxford University Hospitals United Kingdom.
This further showcases Orthocell’s exciting pipeline opportunities which are strongly complimentary to our current regenerative medicine approaches.
Help employers find you! Check out all the jobs and post your resume.